Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate

Ryo Yamauchi; Yasuaki Takeyama; Kazuhide Takata; Atsushi Fukunaga; Kunitoshi Sakurai; Takashi Tanaka; Hiromi Fukuda; Sho Fukuda; Hideo Kunimoto; Kaoru Umeda; Daisuke Morihara; Keiji Yokoyama; Makoto Irie; Satoshi Shakado; Shotaro Sakisaka; Fumihito Hirai

doi:10.2169/internalmedicine.3805-19

This article has now been updated. Please use the final version.

Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate

Ryo Yamauchi, Yasuaki Takeyama, Kazuhide Takata, Atsushi Fukunaga, Kunitoshi Sakurai, Takashi Tanaka, Hiromi Fukuda, Sho Fukuda, Hideo Kunimoto, Kaoru Umeda, Daisuke Morihara, Keiji Yokoyama, Makoto Irie, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai

Author information

Ryo Yamauchi
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Yasuaki Takeyama
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Kazuhide Takata
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Atsushi Fukunaga
Department of Hepatology, Hakujuji Hospital, Japan
Kunitoshi Sakurai
Department of Hepatology, Hakujuji Hospital, Japan
Takashi Tanaka
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Hiromi Fukuda
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Sho Fukuda
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Hideo Kunimoto
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Kaoru Umeda
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Daisuke Morihara
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Keiji Yokoyama
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Makoto Irie
Department of Gastroenterology, Fukuoka University Nishiijn Hospital, Japan
Satoshi Shakado
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
Shotaro Sakisaka
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan
General Medical Research Center, Fukuoka University Faculty of Medicine, Japan
Fumihito Hirai
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan

Keywords: hepatitis B virus reactivation, R-CHOP, LH-RH agonist

JOURNAL OPEN ACCESS Advance online publication

Article ID: 3805-19

DOI https://doi.org/10.2169/internalmedicine.3805-19

The final version of this article is now available: Vol. 59 (2020), No. 9 pp. 1163-1166

Details

Abstract

An 88-year-old man was admitted for elevated liver enzyme levels. Nine years earlier, the patient had been diagnosed with diffuse large B-cell lymphoma (DLBCL) and undergone rituximab, cyclophosphamide, doxorubicin hydrochloride, oncovin, prednisone (R-CHOP) therapy. This patient previously had had a hepatitis B virus (HBV) infection before chemotherapy. After the chemotherapy, he was administered an LHRH agonist for prostate cancer. We diagnosed him with HBV reactivation because of positive serum HBV-DNA. HBV reactivation can occur a long time after chemotherapy, particularly if another treatment with immunity-altering drugs is added. In such cases, additional surveillance may be required to detect HBV reactivation.

Corresponding author

Register with J-STAGE for free!